

Determinants of Incomplete Asthma Control in Patients with Allergic Rhinitis and Asthma



Asako Oka, MD, PhD^a, Tsunahiko Hirano, MD, PhD^b, Yoshikazu Yamaji, MD^b, Kosuke Ito, MD^b, Keiji Oishi, MD, PhD^c, Nobutaka Edakuni, MD, PhD^b, Reo Kawano, MS^d, and Kazuto Matsunaga, MD, PhD^b *Kurashiki and Ube, Japan*

What is already known about this topic? Allergic rhinitis has a major impact on the asthma condition.

What does this article add to our knowledge? The activity of allergic rhinitis had a significant influence on the degree of asthma control after adjusting for many relevant clinical factors.

How does this study impact current management guidelines? Evaluation of the activity of allergic rhinitis in patients with asthma and adequate treatment are likely to improve asthma control.

BACKGROUND: Characterizing associations between the upper and lower airways is important for asthma management. **OBJECTIVES:** This study aimed to assess the determinants of incomplete asthma control in patients with allergic rhinitis (AR) and asthma.

METHODS: Multiple factors including age, sex, atopy, smoking history, medication use, Asthma Control Questionnaire (ACQ) score, FEV₁, fraction of exhaled nitric oxide (FENO), and rhinitis questionnaire score were examined. AR was defined by rhinitis symptoms and the sensitization to inhaled allergens. ACQ was used to dichotomize the subjects into the incompletely controlled group (ACQ score ≥ 0.75) and the well-controlled group. The factors that contribute to incomplete asthma control were assessed by a multivariate analysis.

RESULTS: A total of 260 patients with AR and asthma were enrolled and 108 patients (42%) were classified as incomplete asthma control. The incompletely controlled group was older ($P < .05$), and had more airflow limitation, more airway inflammation, and more severe rhinitis symptoms (all $P < .001$). In contrast, the well-controlled group was more likely to be

taking nasal corticosteroids (NCSs) ($P < .01$). In a multivariate model adjusted by age, asthma treatment, airflow limitation, and FENO, persistence and severity of rhinitis (odds ratio [OR], 2.57; 95% CI, 1.41-4.70, and OR, 2.00; 95% CI, 1.10-3.65) and nonuse of NCSs (OR, 3.83; 95% CI, 1.50-9.81) were independently associated with incomplete asthma control.

CONCLUSIONS: The persistence and severity of AR and the use of NCSs were associated with the level of asthma control in patients with AR and asthma. Further studies are required to determine whether appropriate treatment of rhinitis would improve asthma control. © 2016 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2017;5:160-4)

Key words: Airflow limitation; Airway inflammation; Atopy; Exhaled nitric oxide; Inhaled corticosteroids; Nasal corticosteroids

Allergic rhinitis (AR) has a major impact on asthma condition.¹⁻⁴ Although the associations between the upper and lower airways are not entirely understood, pathophysiologic events critical to the clinical manifestations of AR and asthma are similar.⁵⁻⁷ Multiple factors have been associated with loss of asthma control in patients with AR and asthma, including rhinitis symptoms, blood eosinophil counts, and sinonasal mucosa thickness assessed by coronal computed tomography.⁷⁻¹⁰ However, most of these studies defined AR by clinical symptoms and/or patient questionnaire, and many studies were *post hoc* analyses.^{9,10} Moreover, despite its high prevalence, there are few studies on the effect of AR therapy on asthma control.⁷ To date, the factors that are associated with asthma control have not been fully elucidated in patients with confirmed atopic AR and asthma.

In this cross-sectional study, we initially evaluated the level of asthma control in adult patients with AR and asthma on inhaled corticosteroid maintenance therapy. AR was defined by rhinitis symptoms and the sensitization to inhaled allergens on the basis of Allergic Rhinitis and its Impact on Asthma (ARIA)¹ guidelines. Next, the individual factors that contribute to impaired asthma control were assessed by a multivariate logistic regression model.

^aDivision of Respiratory Medicine, Kurashiki Kinen Hospital, Kurashiki, Japan

^bDivision of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Japan

^cDivision of Cardiology, Department of Medicine and Clinical Science, Graduate School of Medicine, Yamaguchi University, Ube, Japan

^dCenter for Clinical Research, Yamaguchi University Hospital, Ube, Japan

This work was supported by grant 25461501 from the Japan Society for the Promotion of Science.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication March 30, 2016; revised August 2, 2016; accepted for publication August 10, 2016.

Available online October 1, 2016.

Corresponding author: Tsunahiko Hirano, MD, PhD, Division of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube 755-8505, Japan. E-mail: tsuna@yamaguchi-u.ac.jp.

2213-2198

© 2016 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaip.2016.08.002>

Abbreviations used

ACQ- Asthma Control Questionnaire

AR- Allergic rhinitis

ARIA- Allergic Rhinitis and its Impact on Asthma

FENO- Fraction of exhaled nitric oxide

NCS- Nasal corticosteroid

OR- Odds ratio

METHODS

Study design and patients

This was a cross-sectional study. The patients enrolled came from our hospital-based respiratory clinic. A population of 410 nonsmoking patients with asthma was recruited during the pollen season in Japan (from February 2013 to April 2013). We chose this period to examine whether the activity of AR would affect asthma control in patients. All patients had a history of episodic dyspnea, wheezing, and documented airway reversibility and/or airway hyperresponsiveness. According to Global Initiative for Asthma guidelines,¹¹ asthma therapy was standardized and included inhaled corticosteroid with or without long-acting β_2 -agonist, leukotriene antagonist, or theophylline. Current smokers and patients with more than 10 pack-year smoking history were not included. Also, patients with poor adherence to asthma therapy (defined as <80% adherence calculated by dividing the number of days supplied for a medication by the number of days between the visits) or with other pulmonary diseases such as chronic obstructive pulmonary disease were excluded. We examined atopy, Asthma Control Questionnaire (ACQ) score, forced vital capacity, FEV₁, fraction of exhaled nitric oxide (FENO), and rhinitis questionnaire score approved by the Japanese Global Initiative for Asthma and ARIA committee.^{1,2} Serum specific IgE level for common inhaled allergens (house dust mite, cedar, ragweed, cocksfoot, dog allergen, and cat allergen) was measured by using the ImmunoCAP system (Pharmacia Diagnostics, Uppsala, Sweden). To detect atopy more reliably, positive specific IgE levels were defined as more than 0.7 UA/mL. Positive specific IgE to at least 1 allergen was assumed to confirm atopy. In the present study, patients older than 20 years with confirmed atopic AR and asthma were selected and the subsequent analyses were performed. This study was approved by the local ethics committee (institutional review board 526). Informed consent for using the data was obtained from all patients.

Study assessments

The rhinitis questionnaire validated by Ohta et al² was used to assess the nasal symptoms (Table I).¹ AR was suggested if there was a positive answer to the following question: Do you have any of symptoms including watery runny nose, sneezing, nasal obstruction, or itchy nose when you do not have a cold? The ARIA classification, persistence and severity of AR, and its impact on quality of life were also evaluated.¹ The ACQ is a composite measure that assesses the asthma condition according to 5 items.^{12,13} The overall score was the mean of the 5 responses, and an ACQ score of 0.75 or more was considered to indicate incompletely controlled asthma.¹² Both questionnaires have been used in earlier studies.^{2,8} The forced vital capacity and FEV₁ were measured using a dry rolling seal spirometer (CHESTAC-8800; Chest, Tokyo, Japan). The FENO was measured by an online nitric oxide analyzer at a constant flow rate of 50 mL/s (NIOX MINO; Aerocrine, Solana, Sweden). Repeated exhalations were performed to obtain 2 acceptable measurements that agreed

TABLE I. AR patient questionnaire¹

Question 1, Do you have any of these symptoms?*		
Watery runny nose	Yes	No
Sneezing, especially violent and in bouts	Yes	No
Nasal obstruction (feeling of being unable to breathe through your nose)	Yes	No
Itchy nose	Yes	No
Watery, red, itchy eyes	Yes	No
Question 2, What are these symptoms like?†		
Do you have symptoms more than 4 d/wk?	Yes	No
Do you have symptoms for more than 4 wk in a row?	Yes	No
Do your symptoms disturb your sleep?	Yes	No
Do your symptoms restrict your daily activities (sports, leisure, etc)?	Yes	No
Do your symptoms restrict your participation in school or work?	Yes	No
Do your symptoms seem troublesome to you?	Yes	No

Persistent rhinitis means that the symptoms are present for more than 4 d/wk and for more than 4 wks in a row. Moderate/severe rhinitis means that 1 or more of the following items are present: sleep disturbance, impairment of daily activities, leisure, and/or sport, impairment of school or work, troublesome symptoms.

*Question 1 asks about symptoms highly specific to AR.

†Question 2 asks the persistence and severity of rhinitis and impact on quality of life.

within 10% deviation, and the average of these 2 values was registered.¹⁴

STATISTICAL ANALYSIS

The study subjects were dichotomized into 2 groups on the basis of ACQ scores. We labeled those with scores of less than 0.75 as the well-controlled group and those with scores of more than 0.75 as the incompletely controlled group.¹² Comparisons between the 2 groups were performed by chi-square test and Mann-Whitney *U* tests. Multivariate logistic regression model was used to assess the relative associations between the binary outcome (ACQ score $\geq$ 0.75) and a set of covariates. The odds ratios (ORs) with 95% CIs were estimated. The variables with *P* values of less than .05 in the univariate analysis were included in this model. Data were expressed as mean values $\pm$ SD. A *P* value of less than .05 was considered statistically significant.

RESULTS

The study design is shown in Figure 1. A total of 260 patients with AR and asthma were analyzed (Table II). An aggregated ACQ score of 0.75 or more, indicating incomplete asthma control, was found in 108 patients (42%). Patients with incompletely controlled asthma were more likely to be older ($P < .05$), have a lower FEV₁, and higher levels of exhaled NO (all $P < .001$) despite receiving more intensive asthma treatment (daily dose of inhaled corticosteroid and long-acting β_2 -agonist use) compared with the well-controlled group. The incompletely controlled group was more likely than the well-controlled group (18%) to have moderate/severe persistent AR (44%), but only 50% of the patients had been receiving any rhinitis treatments including leukotriene antagonist, antihistamines, or nasal corticosteroids (NCSs). The well-controlled group was more likely to be taking NCS ($P < .01$). In a multivariate model adjusted by age, asthma therapy, airflow limitation, and FENO, persistence and severity of AR (OR, 2.57; 95% CI, 1.41–4.70; $P < .005$ and




FIGURE 1. Study diagram illustrating the number of patients with both asthma with AR for analysis.

TABLE II. Characteristics of patients with asthma and AR by ACQ levels

Characteristics	Well-controlled asthma (ACQ score <0.75)	Incompletely controlled asthma (ACQ score ≥0.75)	P value
No. of females/males	98/54	61/47	.20
Age (y), mean ± SD	50.8 ± 16.2	57.5 ± 16.3	<.05
Body mass index (kg/mm ²), mean ± SD	23.1 ± 3.5	23.8 ± 4.0	.14
Ex-smokers, n (%)	30 (19.7)	30 (27.8)	.13
ACQ score, mean ± SD	0.22 ± 0.22	1.28 ± 0.52	<.001
FVC (L), mean ± SD	3.19 ± 0.92	3.04 ± 0.93	.20
FVC % of predicted (%)	102.1 ± 12.7	99.1 ± 14.8	.08
FEV ₁ (L)	2.48 ± 0.79	2.22 ± 0.79	<.05
FVC/FEV ₁ ratio (%)	77.6 ± 11.4	74.1 ± 10.1	<.05
FEV ₁ % of predicted (%)	95.0 ± 14.4	88.0 ± 17.7	<.001
FENO (ppb)	24.7 ± 18.5	37.3 ± 26.5	<.001
ARIA classification of AR, n (%)			<.001
Mild intermittent	83 (54.6)	23 (21.3)	—
Moderate/severe intermittent	27 (17.8)	20 (18.5)	—
Mild persistent	15 (9.9)	17 (15.7)	—
Moderate/severe persistent	27 (17.8)	48 (44.4)	—
Dose of inhaled corticosteroids (μg/d), mean ± SD*	363 ± 156	417 ± 171	<.01
Inhaled long-acting β ₂ -agonists, n (%)	91 (59.9)	82 (75.9)	<.01
Leukotriene antagonists, n (%)	55 (36.2)	48 (44.4)	.18
Oral antihistamines, n (%)	43 (28.3)	21 (10.4)	.10
NCSs, n (%)	30 (19.7)	8 (7.4)	<.01
Patients with any rhinitis treatment, n (%)	77 (50.7)	54 (50.0)	.90

FVC, Forced vital capacity.

P values compared between the groups.

*Inhaled corticosteroids, expressed as fluticasone propionate equivalent.

OR, 2.00; 95% CI, 1.10-3.65; $P < .01$) and nonuse of NCSs (OR, 3.83; 95% CI, 1.50-9.81; $P < .01$) were independently associated with incomplete asthma control (Table III; area under the curve, 0.78). As shown in Figure 2, there was a significant difference in the ACQ score with or without NCS therapy in patients with moderate/severe persistent AR ($P < .05$).

Significant differences in the ACQ score were not observed in the presence or absence of the use of antihistamines and leukotriene antagonist (Table II).

DISCUSSION

This cross-sectional study shows that almost half of the patients with AR and asthma had impaired asthma control assessed by the ACQ score, and the persistence and severity of AR and the use of NCS were associated with the level of asthma control independent of airflow limitation and airway inflammation. These results suggest that evaluation of rhinitis activity in patients with AR and asthma and its treatment with NCS may contribute to improved asthma control.

TABLE III. Multivariate logistic regression analysis with ACQ score of ≥ 0.75 as the outcome*

Characteristics	Patients with asthma and AR (n = 260) (AUC = 0.78)	
	OR (95% CI)	P value
Age	1.00 (0.99-1.03)	.22
FEV ₁ % of predicted	1.01 (0.97-1.02)	.14
FENO	1.02 (0.99-1.03)	.10
Moderate/severe AR*	2.00 (1.10-3.65)	<.01
Persistent AR*	2.57 (1.41-4.70)	<.005
Daily dose of inhaled corticosteroids	1.00 (0.99-1.00)	.53
Nonuse of inhaled long-acting β_2 -agonists	0.54 (0.27-1.05)	.16
Nonuse of NCSs*	3.83 (1.50-9.81)	<.01

AUC, Area under the curve.

*Independent predictors of incomplete asthma control assessed by ACQ.




FIGURE 2. Mean ACQ score in the study patients subdivided by the ARIA classification of AR and use of NCSs. Data are presented as means $\pm$ SEM. * $P < .05$ vs nonuse of NCSs in patients with moderate/severe persistent AR.

The presence of AR is associated with poor asthma control.^{1,2,4} However, there is little information about the association between the activity of AR and asthma.^{9,10} A recent study of patients with severe asthma reported an inverse correlation between the severity of rhinitis and asthma control and the level of quality of life.⁹ Also, patients with severe asthma commonly have severe nasal disease including chronic rhinosinusitis.^{10,15} In this study, we added a more detailed analysis of the relationship between the activity of AR and asthma using a multivariate logistic regression model.

The main finding of our study was that the activity of AR had a significant influence on the degree of asthma control, even after adjustment by potential confounders. This suggests that there is potentiation of risk for impaired asthma control by the presence of uncontrolled AR. There are some possible explanations for the current observation. Because the study was performed in a hospital-based respiratory clinic, the levels of severity of asthma included in this study were different from those in primary care facilities and asthma was well controlled in most (58%) patients by the conventional treatment. However, they tended to have

more severe rhinitis symptoms compared with those in a survey mainly assessed by general practitioners in Japan.² Despite the remaining nasal symptoms, only 14% of the patients had been receiving the rhinitis treatment with NCSs. This undertreatment for comorbid AR may be caused by either underreporting by patients or poor recognition of rhinitis symptoms by chest physicians. We have recently reported that FENO levels were increased with the activity of AR.⁸ Unexpectedly, in a multivariate model, we found no statistical association between the impaired asthma control and FENO levels. However, this is in agreement with previous studies describing that multiple factors other than AR including asthma therapy, exposure to perennial allergen, smoking history, and blood eosinophils are associated with the level of FENO.¹⁶⁻¹⁹

It is still controversial whether the treatment of AR helps to improve asthma control.²⁰⁻²⁴ The present study shows that there is a significant difference in ACQ level with versus without NCS therapy in patients with moderate/severe persistent AR. These data support a recent study showing the potential role of NCSs in asthma control in children.⁷ In our study, only half of the patients had been receiving any treatment for AR, which was similar to previous studies in children⁷ and adults,⁹ describing that undertreatment of AR in asthma is still a common problem. We suggest that the evaluation of ARIA classification may have a value for stratifying the patients who can be expected to show improved asthma control by AR treatment. However, randomized controlled trials are required to confirm our observational findings.

This study had several limitations. First, it may be argued that our definition of AR was nonspecific, and this may comprise AR and other causes of rhinitis. However, all patients had rhinitis symptoms and atopy, and AR is usually defined in the same way as in our study in everyday practice and research.^{7,9,20-24} Next, some symptoms caused by AR such as cough and throat discomfort may be confused with asthma symptoms by patients. We did not include lung function and exacerbation data to assess the level of asthma control. Thus, it is possible that some patients were classified as incompletely controlled asthma but were not. Third, current smokers and patients with poor adherence to asthma treatment were excluded. Fourth, because only less than 20% of the patients with well-controlled asthma were using NCSs, it is still unclear whether the use of NCSs is effective for all patients with AR and asthma. Furthermore, the survey period of this study was confined to the pollen season to elucidate the symptoms of AR, while a comparison with other seasons was not made. Therefore, there might be a selection bias in this study and the current findings may not be extrapolated to a real-life population of patients with AR and asthma.

In conclusion, the persistence and severity of AR and the use of NCSs were associated with the level of asthma control in patients with AR and asthma. Despite AR's impact on asthma control and quality of life, it is still undertreated. Evaluation of the activity of AR in patients with asthma and adequate treatment with NCSs are likely to improve asthma condition. However, as noted above, randomized controlled trials of NCS use in patients with asthma and AR are needed to determine whether such treatment of AR would improve asthma control.

Acknowledgment

We thank Mr Brent Bell for reading the manuscript.

REFERENCES

1. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. *Allergy* 2008; 63:8-160.
2. Ohta K, Bousquet PJ, Aizawa H, Akiyama K, Adachi M, Ichinose M, et al. Prevalence and impact of rhinitis in asthma. SACRA, a cross sectional nationwide study in Japan. *Allergy* 2011;66:1287-95.
3. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population based study. *Lancet* 2008;372:1012-4.
4. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis. *Clin Exp Allergy* 2005;35:723-7.
5. Beeh KM, Beier J, Kornmann O, Meier C, Taeumer T, Buhl R. A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. *Clin Exp Allergy* 2003;33:475-82.
6. Braunstahl G, Overbeek SE, Kleinjan A, Prins J, Hoogteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. *J Allergy Clin Immunol* 2001;107:469-76.
7. de Groot EP, Nijkamp A, Duiverman EJ, Brand PL. Allergic rhinitis is associated with poor asthma control in children with asthma. *Thorax* 2012;67:582-7.
8. Oka A, Matsunaga K, Kamei T, Sakamoto Y, Hirano T, Hayata A, et al. Ongoing allergic rhinitis impairs asthma control by enhancing the lower airway inflammation. *J Allergy Clin Immunol Pract* 2014;2:172-8.
9. Ponte EV, Franco R, Nascimento HF, Souza-Machado A, Cunha S, Barreto ML, et al. Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. *Allergy* 2008;63:564-9.
10. Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. *J Allergy Clin Immunol* 2001;107:73-80.
11. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Workshop report 2014. Available from: http://www.globalasthma-report.org/Global_Asthma_Report_2014.pdf. Accessed March 1, 2016.
12. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. *Respir Med* 2006;100:616-21.
13. Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respir Med* 2005;99:553-8.
14. Matsunaga K, Hirano T, Kawayama T, Tsuburai T, Nagase H, Aizawa H, et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. *Allergol Int* 2010;59:363-7.
15. Ten Brinke A, Grootendorst DC, Schmidt JT, Bruine FT, van Buchem MA, Sterk PJ, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. *J Allergy Clin Immunol* 2002;109:621-6.
16. An official ATS clinical practice guideline. Interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. *Am J Respir Crit Care Med* 2011;184:602-15.
17. Dweik RA, Sorkness RL, Whenzel S, Hammel J, Curran-Everett D, Comhair SAA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. *Am J Respir Crit Care Med* 2010;181:1033-41.
18. Matsunaga K, Yanagisawa S, Hirano T, Ichikawa T, Koarai A, Akamatsu K, et al. Associated demographics of persistent exhaled nitric oxide elevation in treated asthmatics. *Clin Exp Allergy* 2012;42:775-81.
19. Matsunaga K, Hirano T, Akamatsu K, Koarai A, Sugiura H, Minakata Y, et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. *Allergol Int* 2011;60:331-7.
20. Ribeiro de Andrade C, Chatkin JM, Fiterman J, Scaglia N, Camargos PA. Unified disease, unified management: treating allergic rhinitis and asthma with nasally inhaled corticosteroid. *Respir Med* 2010;104:1577-80.
21. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. *J Allergy Clin Immunol* 2002;109:57-62.
22. Dahl R, Nielsen LP, Kips J, Foresi A, van Cauwenberge P, Tudoric N. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. *Allergy* 2005;60:875-81.
23. Nair A, Vaidyanathan S, Clearie K, Williamson P, Meldrum K, Lipworth BJ. Steroid sparing effects of intranasal corticosteroids in asthma and allergic rhinitis. *Allergy* 2010;65:359-67.
24. Scichilone N, Arrigo R, Paterno A, Santagata R, Impellitteri S, Braido F, et al. The effect of intranasal corticosteroids on asthma control and quality of life in allergic rhinitis with mild asthma. *J Asthma* 2011;48:41-7.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.